Improved models for analysis of T cell immunity against COVID-19
| Reference number | |
| Coordinator | Redoxis AB |
| Funding from Vinnova | SEK 730 000 |
| Project duration | October 2020 - May 2021 |
| Status | Completed |
| Venture | Innovations to mitigate the crisis |
| Call | Finding new ways in the time of a crisis |
Important results from the project
The aim of the study was to evaluate whether Cellevate´s 3D technology for cell culture would provide increased sensitivity and specificity in the analysis of COVID-19 T cell immunity. This is to be able to better evaluate the effects of vaccines and possible immunity, both in preclinical development and clinically.
Expected long term effects
** Denna text är maskinöversatt ** In the project, we have used published methods to investigate Covid-19 specific T cell responses and compared results from conventional 2D cell culture and cell culture in 3D platform. We have seen some improvement in sensitivity and variation in the use of 3D culture plates, but the results need to be confirmed with samples from a larger number of patients to be conclusive. Results from this study have also contributed to the implementation of 3D cell culture in other T cell based assays and are now marketed by Redoxis / Cellevate.
Approach and implementation
Within the project, we have developed the cell culture platform and produced the plates that have been used. We have validated and compared the platform with conventional 2D plate culture in cells from healthy volunteers and Covid-19 patients. T cell response (antigen-specific and unspecific) has been evaluated in several different aspects (proliferation, activation markers, cytokines). We have also prepared marketing material.